Cilostazol - A new approach for the treatment of peripheral occlusive artery disease;Cilostazol - Ein neuer ansatz zur behandlung der pAVK

Vasomed

Volumn 19, Issue 3, 2007, Pages 112-116

  Schrör, Karsten ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Antiplatelet therapy; Cilostazol; Gene regulation; Peripheral arterial disease (PAD)

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; CILOSTAZOL; CLOPIDOGREL; CYCLIC AMP; DEHYDROCILOSTAZOL; HYDROXYCILOSTAZOL; LIPID; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PROSTAGLANDIN DERIVATIVE; UNCLASSIFIED DRUG;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; DRUG MECHANISM; EXERCISE; FIBRINOLYSIS; HUMAN; LEUKOCYTE; LIMB ISCHEMIA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; THROMBOCYTE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 34447326717     PISSN: 09421181     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Bradbury W: The role of cilostazol (Pleta®) in the management of intermittent claudication. Int J Clin Pract 2003; 57: 405-409
2. Cone J, Wang S, Tandon N et al.: Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J Cardiovasc Pharmacol 1999; 34: 497-504
3. Dalainas I: Cilostazol in the management of vascular diseases. Int Angiol 2007; 26: 1-7
4. Douglas JS Jr, Holmes DR, Kereiakes DJ et al.: Coronary stent restenosis in patients treated with cilostazol. Circulation 2005; 112: 2826-2832
5. Elam MB, Heckman J, Crouse JR et al.: Effect of the novel antiplatelet agent cilostazol on Plasma lipoproteins in patients with intermittent claudication. Atheroscler Thromb Vasc Biol 1998; 18: 1942-1947
6. Hiatt WR: Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-1621
7. Hobbs SD, Marshall T, Fegan C et al.: The effect of supervised exercise and cilostazol on coagulation and fibrinolysis in intermittent claudication: A randomized controlled trial. J Vasc Surg 2007; 45: 65-70
8. Kayanoki Y, Che W, Kawata S et al.: The effect of cilostazol, a cyclic nucleotide phosphodiesterase III inhibitor, on heparin binding EGF-like growth factor expression in macrophages and vascular smooth muscle cells. Biochem Biophys Res Comm 1997; 238: 478-481
9. Kim JS, Lee KS, Kim YI et al.: A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: analysis with quantitative bleeding time and platelet aggregation test. J Clin Neurosci 2004; 11: 600-602
10. Kim KY, Shin HK, Choi JM et al.: Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells. J Pharmacol Exp Ther 2002; 300: 709-715
11. Kim MJ, Park KG, Lee KM et al.: Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F. Hypertension 2005; 45: 552-556
12. Kwon SU, Cho Y-J, Koo J-S et al.: Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis. Stroke 2005; 36: 782-786
13. Liu Y, Fong M, Cone J et al.: Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. J Cardiovasc Pharmacol 2000; 36: 351-360
14. Mannava K, Money SR: Current management of peripheral arterial occlusive disease: a review of pharmacologic agents and other interventions. Am J Cardiovasc Drugs 2007; 7: 59-66
15. Minami N, Suzuki Y, Yamamoto M et al.: Inhibition of shear-stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterases in vitro and ex vivo. Life Sci 1997; 61: PL383-389
16. Nishio Y, Kashiwagi A, Takahara N et al.: Cilostazol, a cAMP phosphodiesterase inhibitor, attentuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor alpha in vascular endothelial cells. Horm Metab Res 1997; 29: 491-495
17. Nomura S, Shouzu A, Omoto S et al.: Effect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes. Thromb Haemost 1998; 80: 388-392
18. Nomura S, Inami N, Iasaka T et al.: Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole. Platelets 2004; 15: 167-172
19. Otsuka Pharmaceuticals. Data on file. FDA Advisory Committee Meeting Dossier. Zitiert bei 21.
20. Park SY, Lee JH, Kim CD et al.: Cilostazol suppresses superoxide production and expression of adhesion molecules in human endothelial cells via mediation of cAMP-dependent protein kinase-mediated Maxi-K channel activation. J Pharmacol Exp Ther 2006; 317: 1238-124521.
21. Schrör K: The pharmacology of cilostazol. Diab Obesity Metab 2002; 4 (Suppl 2): S4-S19
22. Shin HK, Kim YK, Lee JH et al.: Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectine-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation 2004; 109: 1022-1028
23. Wang T, Elam MB, Forbes WP et al.: Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication. Atherosclerosis 2003; 171: 337-342
24. Wilhite DB, Comerota AJ, Schmieder FA et al.: Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 2003; 38: 710-713